Sign In
Media & Investors
Skip Navigation LinksSanten > EMEA > Media & Investors > News > Santen announces appointment of Paolo Casati
Contact
Santen Pharmaceutical welcomes your inquiries and opinions.

Santen announces appointment of Paolo Casati

12/3/2014

Milano, Italy – December 3, 2014 (US-EST) – Following the launch of Santen in Italy in October 2014, Santen Italy s.r.l (Milano, Italy) (Santen) today announces that Paolo Casati has been named General Manager of Santen Italy, effective November 21st, 2014.

 

Paolo brings 30 years of top-level management experience and global business leadership in ophthalmic sector. From 2012 to 2014 Paolo served as Head of Sales Force Effectiveness at Alcon (EMEA – Geneva), one of the global leader in eye care that develops and manufactures medicines and devices to serve the full life cycle of eye care needs. During the twenty preceding years, he held at Alcon senior leadership positions in Sales and Marketing departments.

 

Throughout his career, Paolo Casati has managed businesses successfully both in terms of growth and earnings. In this position he was responsible to improve and optimize, Sales Forces Effectiveness, by implementing best-in-class execution, business analytics and management processes. He also created the EMEA Training Organization covering for all Business Units, Technical, Sales, Management & Marketing skills.

 

Paolo Casati, General Manager of Santen in Italy, comments: "Santen group is successful thanks to its commitment to the protection and improvement of eyesight and the quality of life of patients. I am very excited to join the team to establish Santen Italy as one of major company of reference for ophthalmic world in Italy."

 

Masamichi Sato, Head of Santen European group and President of Santen Holdings EU BV, concludes: "Our expansion in Italy is an important step in achieving global presence in Europe. Paolo Casati's appointment will bring leadership that fits very well with the company's ambition and values". 

About Santen

As a specialty company dedicated to the ophthalmic and anti-rheumatic fields, Santen carries out the research, development, sales, and marketing of pharmaceuticals. The company has 15 bases in 12 countries globally and delivers products to consumers in more than 50 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.

Santen Forward-looking Statements

Information provided in this press release contains so-called "Forward-looking Statements". The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

 

This press release is also prepared in other languages. However this English document is the original document, and documents prepared in other languages are for your reference only. In case of any discrepancy between the English and translated versions, the English version will prevail. Please refer to http://www.santen.eu for the original English document.

Contacts

​Media Relations

Nicolas Merigeau

Emmanuel Huynh

NewCap.

nmerigeau@newcap.fr

Tel: +33-1-4471-9498

Santen

Geneviève Garrigos

Corporate Communication Director - Santen Europe          

Tel: +33-6-6554-6019